| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 03/25/2004 | WO2004024888A2 WNHs AS MODIFIERS OF p53, p21, AND BRANCHING MORPHOGENESIS PATHWAYS AND METHODS OF USE |
| 03/25/2004 | WO2004024887A2 Centrosome proteins and uses thereof |
| 03/25/2004 | WO2004024884A2 Syts as modifiers of the p21 pathway and methods of use |
| 03/25/2004 | WO2004024882A2 FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 03/25/2004 | WO2004024881A2 LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 03/25/2004 | WO2004024880A2 AMPDs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 03/25/2004 | WO2004024879A2 RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 03/25/2004 | WO2004024877A2 Human kininogen d3 domain polypeptide as an anti-angiogenic and anti-tumor agent |
| 03/25/2004 | WO2004024873A2 CORE 1 β3-GALACTOSYLTRANSFERASE SPECIFIC MOLECULAR CHAPERONES, NUCLEIC ACIDS, AND METHODS OF USE THEREOF |
| 03/25/2004 | WO2004024869A2 Cancer associated antigens, sga-56m and sga-56mv, and uses thereof |
| 03/25/2004 | WO2004024863A2 Adenoviral va1 pol iii expression system for rna expression |
| 03/25/2004 | WO2004024862A2 Yeast protein expression secretion system |
| 03/25/2004 | WO2004024777A1 Hydroxyalkyl starch derivatives |
| 03/25/2004 | WO2004024776A1 Method of producing hydroxyalkyl starch derivatives |
| 03/25/2004 | WO2004024770A1 Polyclonal antibodies, preparation method thereof and use of same |
| 03/25/2004 | WO2004024769A2 Ostertagia vaccine |
| 03/25/2004 | WO2004024766A1 Kdr peptides and vaccines containing the same |
| 03/25/2004 | WO2004024765A1 Crystal structure of an angiotensin-converting enzyme (ace) and uses thereof |
| 03/25/2004 | WO2004024764A1 Pharmaceutical composition and medical treatments comprising notch ligand proteins |
| 03/25/2004 | WO2004024763A1 Hb-954 as a target for modulating angiogenesis |
| 03/25/2004 | WO2004024762A2 Il-8 like protein |
| 03/25/2004 | WO2004024761A1 Hasylated polypeptides, especially hasylated erythropoietin |
| 03/25/2004 | WO2004024760A1 Novel protein and dna thereof |
| 03/25/2004 | WO2004024759A1 Methods and reagents for modulating cell proliferation |
| 03/25/2004 | WO2004024756A2 Orthopoxvirus antigens and use thereof |
| 03/25/2004 | WO2004024753A1 Process for manufacturing crystals of growth hormone |
| 03/25/2004 | WO2004024182A2 Method for isolating hepatitis c virus peptides |
| 03/25/2004 | WO2004024180A1 Lactoferrin compositions and methods of wound treatment |
| 03/25/2004 | WO2004024175A1 Cancer antigen peptide preparation |
| 03/25/2004 | WO2004024173A2 A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism |
| 03/25/2004 | WO2004024097A2 Compositions and methods for the treatment of immune related diseases |
| 03/25/2004 | WO2004024092A2 Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| 03/25/2004 | WO2004024088A2 Design of chemokine analogs for the treatment of human diseases |
| 03/25/2004 | WO2004024087A2 Methods of diagnosing and treating hyperproliferative disorders |
| 03/25/2004 | WO2004024084A2 Rb pahtway and chromatin remodeling genes that antagonize let-60 ras signaling |
| 03/25/2004 | WO2004024077A2 Novel composition and methods for the treatment of psoriasis |
| 03/25/2004 | WO2004024076A2 Novel compositions and methods for the treatment of immune related diseases |
| 03/25/2004 | WO2004024075A2 Chemokine receptor antagonists as therapeutic agents |
| 03/25/2004 | WO2004024072A2 Novel compositions and methods for the treatment of immune related diseases |
| 03/25/2004 | WO2004024069A2 Novel compositions and methods for the treatment of immune-related diseases |
| 03/25/2004 | WO2004024068A2 Novel composition and methods for the treatment of immune related diseases |
| 03/25/2004 | WO2004024064A2 Compositions and methods for the diagnosis and treatment of tumor |
| 03/25/2004 | WO2004024063A2 Compositions and methods for the diagnosis and treatment of tumor |
| 03/25/2004 | WO2004023973A2 Molecules for diagnostics and therapeutics |
| 03/25/2004 | WO2004023870A1 Human slt transgenic animal |
| 03/25/2004 | WO2004023869A1 Use of plag or plag-inhibitors to diagnose and/or treat disease |
| 03/25/2004 | WO2004023867A2 Transgenic cancer models in fish |
| 03/25/2004 | WO2004018511A3 Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins |
| 03/25/2004 | WO2004016811A3 Methods and kit for genes shuffling using tagged primers |
| 03/25/2004 | WO2004016274A3 Novel peptide-conjugated oligomeric compounds |
| 03/25/2004 | WO2004009819A3 Polypeptides with a signal sequence comprising an fivsi motif and olynucleotides encoding therefor |
| 03/25/2004 | WO2004009624A3 Three finger toxin fold protein |
| 03/25/2004 | WO2004009621A3 Polypeptides of nontypeable haemophilus influenzae |
| 03/25/2004 | WO2004007722A3 Transgenic animal expressing alzheimer’s tau protein |
| 03/25/2004 | WO2004007719A8 Use of sumo- and ubiquitin-modified pcna for detection and channeling of dna transaction pathways |
| 03/25/2004 | WO2004007718A3 Rna-interference by single-stranded rna molecules |
| 03/25/2004 | WO2004007660A3 Novel hsf transcription factors and use thereof in transgenic plants |
| 03/25/2004 | WO2004005346A8 Human nuclear hormone receptor |
| 03/25/2004 | WO2004003011A3 Nuclear hormone receptor |
| 03/25/2004 | WO2004000233A3 Algal gdp-mannose-3',5'-epimerases and methods of use thereof |
| 03/25/2004 | WO2003105890A3 Vaccine comprising mixtures of multivalent meningococcal outer membrane vesciles |
| 03/25/2004 | WO2003104441A3 Bacterial strain, compositions derived therefrom and methods of using same for treating beta-amyloid peptide-associated deseases |
| 03/25/2004 | WO2003104261A3 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 03/25/2004 | WO2003100001A3 Claudin polypeptides, polynucleotides, and methods of making and use thereof |
| 03/25/2004 | WO2003099993A3 Dna sequence confering early and increased secondary metabolite production in streptomyces and method of use |
| 03/25/2004 | WO2003097677A3 Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus |
| 03/25/2004 | WO2003097668A3 Novel process for production of the somatostatin analog, octreotide |
| 03/25/2004 | WO2003095968A3 Method for simultaneously detecting an antigen and an antibody of an infectious microorganism |
| 03/25/2004 | WO2003093485A3 Optimization of transgene expression in mammalian cells |
| 03/25/2004 | WO2003093314A3 Connective tissue stimulating peptides |
| 03/25/2004 | WO2003092735A3 Peptide nucleic acid conjugates with beta-amino acid polymers or reptoids |
| 03/25/2004 | WO2003091401A3 Multi plasmid system for the production of influenza virus |
| 03/25/2004 | WO2003088996A3 Lewis y epitope modified polypeptide, or mucin fusion polypetide, tumor vaccines |
| 03/25/2004 | WO2003087340A3 Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| 03/25/2004 | WO2003087154A3 Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments |
| 03/25/2004 | WO2003086326A3 G-type peptides to ameliorate atherosclerosis |
| 03/25/2004 | WO2003085375A3 Hcv antiviral and cytotoxicity drug screening assay |
| 03/25/2004 | WO2003085103A3 Purified polypeptides involved in nucleotide hydrolysis |
| 03/25/2004 | WO2003084565A3 Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
| 03/25/2004 | WO2003082908A3 Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein |
| 03/25/2004 | WO2003082902A3 Novel corticotropin-releasing hormone analogs |
| 03/25/2004 | WO2003081993A3 Transgenic aves producing human polyclonal antibodies |
| 03/25/2004 | WO2003081988A3 Generation of plants with improved drought tolerance |
| 03/25/2004 | WO2003076636A3 Process for the preparation of l-amino acids using strains of the enterobacteriaceae family |
| 03/25/2004 | WO2003076591A3 Compositions and methods for generating an immune response |
| 03/25/2004 | WO2003074677A3 MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
| 03/25/2004 | WO2003074663A3 MP21s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 03/25/2004 | WO2003074553A3 Expec-specific proteins, genes encoding them and uses thereof |
| 03/25/2004 | WO2003074546A3 Streptavidin-binding peptide |
| 03/25/2004 | WO2003072804A3 Nanostructures containing pilin protein |
| 03/25/2004 | WO2003072195A3 Method for administering glp-1 molecules |
| 03/25/2004 | WO2003066857A3 Elements for modulating plant dna replication, transformation rate, cell cycle regulation and growth |
| 03/25/2004 | WO2003060088A3 Viral vaccine production method |
| 03/25/2004 | WO2003059374A3 Use of dimer-specific nuclear localisation signal peptides (dsnls) derived from the stat dna binding domain |
| 03/25/2004 | WO2003057823A3 Epitope synchronization in antigen presenting cells |
| 03/25/2004 | WO2003056023A8 Double-stranded cyclic dna capable of proliferating as artificial e. coli chromosome |
| 03/25/2004 | WO2003054156A3 Novel g proein-coupled receptor, gave7 |
| 03/25/2004 | WO2003051923A3 Novel g-protein coupled receptors and dna sequences thereof |
| 03/25/2004 | WO2003048767A3 Use of elavl-1 gene in the detection and modulation of apoptosis |
| 03/25/2004 | WO2003048195A3 Glucose dependant release of insulin from glucose sensing insulin derivatives |